Section Arrow
ASND.NASDAQ
- Ascendis Pharma A/S
Quotes are at least 15-min delayed:2026/07/21 17:18 EDT
After Hours
Last
 255.2
0 (0.00%)
Bid
250.03
Ask
267.58
High 255.88 
Low 255.2 
Volume 17.49K 
Regular Hours (Closed)
Last
 255.2
+3.44 (+1.37%)
Day High 
257.12 
Prev. Close
251.76 
1-M High
282.15 
Volume 
549.02K 
Bid
250.03
Ask
267.58
Day Low
250.03 
Open
252.72 
1-M Low
222.815 
Market Cap 
16.51B 
Currency 美元 
P/E 29.13 
%Yield -- 
10-SMA 266.2 
20-SMA 261.48 
50-SMA 242.57 
52-W High 282.15 
52-W Low 160.86 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
7.57/13.73
Enterprise Value
16.90B
Balance Sheet
Book Value Per Share
8.47
Cash Flow
Cash Flow Yield
0.00
Income Statement
Total Revenue
720.13M
Operating Revenue Per Share
2.45
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
JUNSJupiter Neurosciences Inc0.1697+0.0047+2.85%-- 
After Hours 0.16175 -0.00795 -4.68%
VIVSVivoSim Lab Inc0.45-0.0549-10.87%0.47PE
After Hours 0.4769 +0.0269 +5.98%
IOVAIovance Biotherapeutics5.48+0.46+9.16%-- 
After Hours 5.5101 +0.0301 +0.55%
GOSSGossamer Bio0.1548+0.0138+9.79%-- 
After Hours 0.154 -0.0008 -0.52%
RXRXRecursion Pharmaceuticals3.08+0.19+6.57%-- 
After Hours 3.08 0 0.00%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.